2020 | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC | Zhu, Viola W; YEN-TING LIN ; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; CHIA-CHI LIN ; Soo, Ross A | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 45 | 36 | |
2023 | A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study) | Ang, Yvonne L E; Zhao, Xiaotian; Reungwetwattana, Thanyanan; Cho, Byoung-Chul; BIN-CHI LIAO ; Yeung, Rebecca; Loong, Herbert H; Kim, Dong-Wan; CHIH-HSIN YANG ; Lim, Sun Min; Ahn, Myung-Ju; Lee, Se-Hoon; Suwatanapongched, Thitiporn; Kongchauy, Kanchaporn; Ou, Qiuxiang; Yu, Ruoying; Tai, Bee Choo; Goh, Boon Cher; Mok, Tony S K; Soo, Ross A | Cancers | 2 | 0 | |